Now showing items 1-10 of 28
Survival outcomes according to TIMP1 and EGFR expression in heavily treated patients with advanced non-small cell lung cancer who received biweekly irinotecan plus bevacizumab
(International Institute of Anticancer Research, 2017)
EGFR exon 20 insertion in lung adenocarcinomas among hispanics (geno1.2-CLICaP)
Objectives Contrasting other EGFR mutations (EGFRm) in lung adenocarcinomas, insertions in exon 20 (exon20ins) are generally associated with resistance to targeted therapy, limiting therapeutic options and impoverishing ...